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Glycine transporter GLYT1 is essential for glycine-mediated
protection of human intestinal epithelial cells against
oxidative damage
Alison Howard, Imran Tahir, Sajid Javed, Sarah M. Waring, Dianne Ford and Barry H. Hirst
Epithelial Research Group, Institute for Cell and Molecular Biosciences, Newcastle University, Faculty of Medical Sciences, Newcastle upon Tyne
NE2 4HH, UK
Glycine protects mammalian intestine against oxidative damage caused by ischaemia-
reperfusion (IR) injury and prevents or reverses experimentally-induced colitis. However
the mechanism of protection remains largely unknown. The objectives of the current study
were to demonstrate directly glycine-mediated protection of human intestinal epithelial cells
and to determine the requirement for glycine uptake by the specific transporter GLYT1.
Exogenous glycine protected human intestinal Caco-2 and HCT-8 cells against the oxidative
agent tert-butylhydroperoxide and reduced the intracellular concentration of reactive oxygen
species, when applied prior to but not concomitant with the oxidative challenge. Glycine given
prior to oxidative challenge preserved intracellular glutathione concentration but had no effect
on the rate of glycine uptake. Protection was dependent on GLYT1 activity, being blocked by
a specific GLYT1 inhibitor, supporting a requirement for intracellular glycine accumulation.
Maintained intracellular glutathione content is indicated as a mechanism through which the
protective effect may in part be mediated. However expression of the genes encoding GLYT1
and the glutathione synthesising enzymes glutamate-cysteine ligase, both catalytic and modifier
subunits, and glutathione synthetase was not altered by glycine or tert-butylhydroperoxide,
suggesting transcriptional regulation is not involved. This work has demonstrated a novel role
of GLYT1 in intestine and shown that intestinal epithelial cells respond directly to oxidative
challenge without reliance on extra-epithelial tissues or functions such as neurone, blood-flow
or immune responses for antioxidant defence. The protective actions of glycine and maintenance
of epithelial antioxidant defences suggest it may be beneficial in treatment of inflammatory bowel
disease.
(Resubmitted 16 December 2009; accepted after revision 25 January 2010; first published online 1 February 2010)
Corresponding author B. H. Hirst: Institute for Cell and Molecular Biosciences, Newcastle University, Faculty of Medical
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Abbreviations CLSM, confocal laser scanning microscopy; GSH, glutathione; GCL, glutamate-cysteine ligase;
GCLC, GCL catalytic subunit; GCLM, GCL modifier subunit; GS, GSH synthetase; γ-GC, γ-glutamylcysteine;
IR, ischaemia–reperfusion; ROS, reactive oxygen species.
Introduction
Glycine is a well-documented cytoprotective agent. During
the last 10–20 years numerous studies have reported the
protective effective of glycine in a broad range of tissues,
including kidney, liver and lung, and against a number
of injurious agents (Weinberg et al. 1990; Silva et al. 1991;
Ligumsky et al. 1995; Ikejima et al. 1996; Zhong et al. 1996).
A small scale clinical trial has shown beneficial effects of
glycine in preventing reperfusion injury of hepatocytes
following human liver transplantation (Schemmer et al.
2002) and the outcome of a follow-up, large scale trial is
awaited (Luntz et al. 2005). In the intestine, the protective
effect of glycine against oxidative damage caused by
ischaemia–reperfusion (IR) injury has been demonstrated
in a variety of animal studies (Mangino et al. 1996;
Iijima et al. 1997; Lee et al. 2001, 2002; Kallakuri et al.
2003), including that sustained during intestinal trans-
plantation (Schaefer et al. 2008). Additionally in rats sub-
jected to abdominal irradiation glycine supplementation
preserved colonic wall thickness and morphology (Diestel
et al. 2007), while dietary glycine also prevented or
reversed experimentally-induced colitis, suggesting a
possible beneficial effect of glycine supplementation
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in inflammatory disease of the bowel (Tsune et al.
2003).
Several mechanisms have been implicated in
contributing to the cytoprotective effects of glycine. These
include stimulation of glutathione synthesis (Jackson,
1986; Jackson et al. 2004), inhibition of glycine-gated
chloride channels (glycine receptors) (Zhong et al. 2003),
inhibition of macrophage activation (Schilling & Eder,
2004) and stimulation of heat-shock proteins (Nissim
et al. 1992). However, the process by which glycine
exerts its protective effect remains uncertain and the
available evidence suggests the likelihood of multiple
mechanisms, which may be either tissue specific or
dependent on the nature of the injurious agent (Sogabe
et al. 1996; Deters et al. 1998). In the intestine, studies
indicate protection by glycine from damage caused during
mesenteric ischaemia is by inhibition of apoptosis (Jacob
et al. 2003), while others have shown that glycine
protection against intestinal IR injury is by a mechanism
consistent with glycine uptake (Lee et al. 2002).
Glycine is a substrate for a number of membrane trans-
port systems in the intestine that may facilitate cellular
uptake. System GLY is unique among glycine trans-
porters in that it is highly substrate specific and has a
high affinity for glycine. Two genes, GLYT1 (SLC6A9)
and GLYT2 (SLC6A5), that encode system GLY-like
activity have been identified, and both are members of
the sodium- and chloride-dependent neurotransmitter
transporter family, SLC6. We have established previously
the expression, localization and functional activity of
the glycine-specific transporter GLYT1 in human small
intestine and model enterocytes, Caco-2 cells. GLYT1 is
localized predominantly at the basolateral membrane of
enterocytes and functions primarily to import glycine into
the cell, suggesting a role in meeting essential requirements
of the enterocyte, rather than in nutrient absorption
(Christie et al. 2001). Consistent with this likely role is the
observed increase in GLYT1 expression in the proximal
intestine of rats transferred to total parenteral nutrition
(Howard et al. 2004).
Since glycine uptake is implicated in the cytoprotective
mechanism of glycine and GLYT1 has been identified
as an important and specific uptake transport system
in the intestinal epithelium, we have investigated the
relationship between glycine cytoprotection and GLYT1 in
the human intestinal cell lines, Caco-2 and HCT-8. HCT-8
cells derive from a human ileo-caecal adenocarcinoma
(Tompkins et al. 1974) and, like the Caco-2 cell line
(Pinto et al. 1983), exhibit structural and functional
characteristics comparable to those of intestinal epithelial
cells. HCT-8 cells form high resistance, polarised mono-
layers in culture with apical microvilli, intercellular
junctional complexes and brush-border enzymes (Allen
et al. 1991). However, whereas differentiated Caco-2 cells
resemble the absorptive enterocytes of the small intestine,
HCT-8 cells are more comparable to colonocytes of the
distal intestine and have proved a useful model to study gut
barrier function and mucosal inflammation (Merendino
et al. 1999; Marion et al. 2005; Leblond et al. 2006),
bacterial invasion (Rogers et al. 2003; Luck et al. 2005;
Hashim et al. 2006) and cell signalling (Merchant et al.
2005).
Methods
Materials
[U-14C]Glycine (specific activity, 103 mCi mmol−1) and
[2-3H]glycine (specific activity, 15.7 Ci mmol−1) were
obtained from GE Healthcare (Little Chalfont, UK).
Cell culture media and supplements were from Sigma
(Poole, UK). Tissue culture plastics and Transwell filter
inserts were obtained from Corning B.V. (Amsterdam,
the Netherlands). Caco-2 and HCT-8 cell lines were
obtained from ATCC (Rockville, MD, USA). Amino acids
and fetal bovine serum were purchased from Sigma.
The specific GLYT1 and GLYT2 inhibitors, N-[3-(4′-
fluorophenyl)-3-(4′-phenylphenoxy)-propyl]sarcosine
(ALX-5407/NFPS) and O-[(2-benzyloxyphenyl-3-
fluorophenyl)methyl]-L-serine) (ALX-1393), respectively,
were purchased from Sigma. Glutathione detection
kit (ApoGSH Glutathione Colorimetric Detection Kit)
was from BioVision (San Francisco, CA, USA). SV
Total RNA extraction kit, Moloney murine leukaemia
virus reverse transcriptase (MMuLV-RT), ribonuclease
inhibitor (RNasin), deoxynucleotide triphosphates
(dNTPs) and pGEM-T-easy cloning kit were from
Promega (Southampton, UK). Hexanucleotide primer
was from GE Healthcare and TAq DNA polymerase
was from ABgene (Glasgow, UK). Goat anti-rat GLYT1
antibody was purchased from Autogen Bioclear (Calne,
Wiltshire, UK). The anti-rat antibodies cross-react with
human GLYT1. AlexaFluor 488-labelled donkey anti-goat
IgG was from Molecular Probes/Invitrogen (Glasgow,
UK). Vectashield mounting medium was from Vector
Laboratories (Burlingame, CA, USA). All other reagents
were from Sigma.
Cell culture
Caco-2 cells (passage number 26–36; ATCC no. HTB-37)
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 4.5 g l−1 glucose, supplemented with
1.2% (w/v) non-essential amino acids, 10% (v/v)
fetal calf serum, 100 U ml−1 penicillin and 100µg ml−1
streptomycin sulphate. HCT-8 cells (passage number
23–40; ATCC no. CCL-244) were cultured in RPMI-1640,
supplemented with 2 mmol l−1 glutamine, 100µg ml−1
streptomycin sulphate, 100 U ml−1 penicillin, 5% (v/v)
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fetal calf serum and 1 mmol l−1 sodium pyruvate. Glycine
concentration in each medium was at physiological levels
(0.03 and 0.01 g l−1 for DMEM and RPMI respectively).
Cells were maintained at 37◦C in a 5% CO2: 95% air
incubator in 162 cm2 flasks (Corning).
For uptake experiments cells were seeded onto
12 mm polycarbonate filters (Transwells, Corning) at
5× 104 cells per well and grown at 37◦C, 5% CO2, in
humidified air with medium replenished every 72 h. Cell
confluence and functional integrity of cell layers was
determined by measuring transepithelial resistance (RT)
using an electrical voltohmeter (EVOM, World Precision
Instruments Inc., Sarasota, FL, USA). Experiments were
performed when RT exceeded 200Ä cm
2 after subtraction
of standard filter RT (100Ä cm
2), usually after 14 days for
Caco-2 and 7 days for HCT-8 cells. For experiments, cells
were transferred into serum-free medium containing the
appropriate additive or into amino acid-free, serum-free
medium for the required period. For the duration of the
experiment, control cells were maintained in serum-free
medium.
For cytotoxicity studies, glutathione measurement and
determination of reactive oxygen species (ROS), cells were
seeded in 96-well plates at a concentration of 1× 104 cells
per well. All experiments were performed 2–3 days after
seeding, when cells were 80–90% confluent, and 18–24 h
after replenishing the medium. For fluorescence assays
(ROS and glutathione (GSH) measurement) solid black
plates were used. Clear plates were used for cytotoxicity
studies and to determine cell confluence at the time of
experimentation.
Cytotoxicity studies
For cytotoxicity studies, culture medium was removed and
the cells rinsed three times in phosphate buffered saline
(PBS). tert-Butyl hydroperoxide (t-BOOH), an organic
hydroperoxide that induces oxidative stress (Tormos et al.
2004), was added to serum-free culture medium to the
desired concentration and the cells incubated in this for
the required time (1–24 h). For cells grown on filters
the electrical resistance was measured both prior to
and at the completion of the treatment period and the
treatment medium was present in both apical and basal
compartments. To investigate the cytoprotective effects
of amino acid pre-treatment, cells were incubated in
serum-free culture medium containing 1 or 5 mmol l−1
glycine or alanine for 24 h, washed three times with PBS
and then incubated in serum-free medium containing
150µmol l−1 t-BOOH for a further 24 h. For concurrent
treatment with glycine and t-BOOH, cell monolayers
were washed three times in PBS and incubated in
serum-free medium containing glycine (1 or 5 mmol l−1)
and t-BOOH (150µmol l−1) for 24 h. At the end of
treatment, cells were washed three times in Krebs buffer
and viability assessed. Control cells were subjected to
the same wash protocol as samples and transferred to
serum-free medium for the treatment period. When
required, mannitol was added to the medium to maintain
osmolarity.
MTT assay
Cell viability was measured using the 3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide
(MTT) assay (Mosmann, 1983). Briefly, HCT-8 cells
were dispensed into 96-well plates at a concentration
of 1× 104 cells per well. Following treatment the cells
were rinsed with PBS. MTT reagent (0.25 mg ml−1) was
added to the cells and incubated for 4 h. One hundred
microlitres of dimethyl sulfoxide was added to the reaction
followed by 25µl of Sorensen’s glycine buffer (0.1 mol l−1
glycine, 0.1 mol l−1 NaCl, pH 10.5) to solubilise the cells.
Absorbance at 570 nm was measured to calculate cell
survival.
Reactive oxygen species measurement
Reactive oxygen species (ROS) were detected and
quantified using the Image-IT Live reactive oxygen
species detection kit (Invitrogen, Paisley, UK). Briefly,
following induction of ROS with t-BOOH, cells were
incubated with 25µmol l−1 5-(and-6)-carboxy-2′,7′-
dichlorodihydrofluorescein diacetate (H2DCFDA) in
Hanks’ buffered salt solution for 30 min at 37◦C, and
nuclei were counterstained with Hoechst 33342, which
binds DNA, and fluorescence measured at 495/592 nm
and 350/461 nm (excitation/emission for the fluorescein
and Hoechst dyes, respectively).
Measurement of reduced glutathione concentration
To determine glutathione levels cells were rinsed twice
with PBS and detached from the plate with trypsin,
centrifuged at 700 g for 5 min at 4◦C, and the cell
pellet resuspended in 0.5 ml ice-cold PBS. Glutathione
concentration (µg mg−1 protein) in the cell pellet was
measured using the ApoGSH Glutathione Colorimetric
Detection Kit (BioVision, Mountain View, CA, USA).
Protein determination
Protein content of the cells was determined in monolayers,
which were grown under identical conditions to those
used for experiments. Cells were lysed for 20 min on ice
in 2% Nonidet P-40, 0.2% SDS, 1 mmol l−1 dithiothreitol
(DTT) in PBS and the lysate homogenized by passing
through a 25 gauge needle several times. The homogenate
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Table 1. Oligonucleotide primers used in real-time PCR assays. Primer sequences are written 5′–3′ with exon location and predicted
Tm and product size
cDNA (Genbank accession no.) Sequence Tm Exon location Product size (bp)
GLYT1 (NM_006934) Forward CCATGTTCAAAGGAGTGGGCTA 62 6 72
Reverse TGACCACATTGTAGTAGATGCCG 63 7
GCLC (NM_000178) Forward CTTGTAGTCAGGATGGTTTGCG 62 1 171
Reverse TCCTGGACTGATCCCAATTCTG 62 2
GCLM (NM_001498) Forward GCAAATGCAGTCAAATCTGGTG 60 4 194
Reverse TCCTTGGAGCATTTACAGCCTTAC 64 5
GS (NM_002061) Forward GTAACCTGCACCAACAATGACG 64 8 91
Reverse CGGTGCCAGCTTAGGAATAACC 64 9
was centrifuged at 13,000 g for 15 min to remove insoluble
debris and total cellular protein was determined using a
modified Bradford assay (Sigma).
Reverse transcription and polymerase chain
reaction (RT-PCR)
Total RNA was extracted from confluent monolayers of
HCT-8 and Caco-2 cells grown on polycarbonate supports
using the SV Total RNA extraction kit. Concentration
of RNA was quantified by measuring absorbance at
260 nm, and RNA integrity was verified by electro-
phoresis on a 1% (w/v) agarose formaldehyde gel
stained with ethidium bromide. Reverse transcription
(RT) was performed by incubating 1µg total RNA,
500 ng random hexamers, 0.5 mmol l−1 each of the four
dNTPS, 1× reaction buffer, 20 U RNasin, and 100 U
MMuLV RT in a final volume of 20µl at 42◦C for 1 h.
Oligonucleotide primers used for the detection of GLYT1
(sequence: 5′, ACTCAGTTCTGCCTCCTGGAGAC; 3′,
AGCCTGGGTACTGGTAGTGG) were synthesized by
VHBio (Newcastle upon Tyne, UK). To demonstrate
expression of GLYT1 in human large intestine, PCR was
performed on a panel of intestinal cDNA samples (Human
Digestive System Multiple Tissue cDNA (MTC) Panel;
Clontech). For comparison purposes, samples of human
ileum, kidney and liver from the same panel were included
in the PCR. Each cDNA sample in the panel is derived
from a pool of non-diseased tissues from several donors
(n= 2–39) harvested post mortem following sudden death.
PCR reactions were performed in a 25µl total
volume containing 2µl RT product, 0.2 mmol l−1 dNTPs,
1µmol l−1 each primer, 2 mmol l−1 MgCl2, 1×PCR buffer
and 1.25 U TAq DNA polymerase (ThermoStart TAq,
ABgene). All PCR reactions used a hot-start procedure
(incubation at 95◦C for 15 min to activate the enzyme
before beginning cycling), 32 cycles of denaturation at
95◦C for 30 s, annealing at 65◦C for 30 s, extension
at 72◦C for 30 s, and a final incubation at 72◦C for
10 min. PCR products were electrophoresed on 1.5%
(wt/vol) agarose/Tris-borate EDTA gels, stained with
ethidium bromide, and analysed on an AlphaInnotech Gel
Document system. PCR products were characterized fully
either by direct sequencing or cloning in pGem-T-easy
(Promega) followed by sequence analysis (Pinnacle,
Newcastle University, Newcastle upon Tyne, UK).
Quantitative PCR (qPCR)
The effect of glycine and t-BOOH on abundance of
mRNAs encoding GLYT1 and enzymes involved in
the synthesis of glutathione (glutamate-cysteine ligase
catalytic and modifier subunits (GCLC and GCLM,
respectively) and glutathione synthetase (GS)) was
measured using relative quantitative real-time PCR.
Primers for each mRNA target were designed using D-LUX
designer software (Invitrogen), and one primer in each
pair was labelled with a suitable fluorophore. Primers
were chosen so that amplicons were less than 200 bp in
length and spanned at least one exon–exon junction to
avoid amplification of residual DNA carried over in the
RNA preparation (Table 1). Confluent monolayers of cells
grown on 12 mm Transwells were treated with glycine or
t-BOOH as described and RNA extracted using the SV
total RNA kit (Promega), which includes a DNAse 1 digest
to remove contaminating genomic DNA. RNA integrity
was determined on an Agilent Bioanalyser and only those
samples with a RIN≥8 were used in PCR analysis. Reverse
transcription was performed on 0.5µg total RNA as
described above using RNaseH+ MMuLV RT (Promega)
and 1µl of the product was amplified in 1× Lightcycler
480 Probes Master (Roche) with 0.5µmol l−1 each primer
(total reaction volume 10µl) on a 96-well Lightcycler 480
(Roche). Titrations were carried out to confirm that the
volume of RT product included in PCR was not inhibitory.
The PCR, performed in duplicate on each sample, involved
an initial denaturation step (95◦C, 10 min) and 45 cycles
of 95◦C for 10 s, 60◦C for 20 s, and 72◦C for 1 s when
fluorescence was measured. Following amplification, melt
curve analysis was carried out to determine the specificity
of products. Representative PCR products were cloned and
sequenced for each target gene and the melt temperature
C© 2010 The Authors. Journal compilation C© 2010 The Physiological Society
) at University of Newcastle on March 18, 2010jp.physoc.orgDownloaded from J Physiol (
J Physiol 588.6 Glycine protection of intestine 999
of these used to identify the correct product in sub-
sequent amplifications. Relative mRNA concentrations
(arbitrary units) were derived from concentration curves
made from serial dilutions of the appropriate cloned PCR
product. In all cases PCR efficiency approached 2 (>1.9)
and was consistent between runs. Data were normalised
to the reference genes GAPDH and hATP5B, selected
using the GeNorm programme (Vandesompele et al. 2002)
(purchased from PrimerDesign, Southampton, UK).
Immunohistochemistry
HCT-8 cell monolayers (7 days after seeding) grown on
filter supports (Transwell; Corning) or 10µm frozen
sections of human colon tissue (purchased from Medical
Solutions plc, Peterborough, UK) were fixed for 30 min
on ice in 2% (w/v) paraformaldehyde in PBS and
permeabilised with 0.1% (v/v) Triton X-100 in PBS for
30 min at room temperature. Samples were blocked with
10% donkey serum in PBS (v/v) for 30 min at 4◦C and after
a PBS wash incubated with goat anti-rat GLYT1 antibody
(1/50 dilution in PBS) overnight at 4◦C. Samples were
washed with PBS before incubation with an AlexaFluor
488-labelled donkey anti-goat IgG (1/80 dilution in PBS)
for 1 h at 4◦C. After washing in PBS samples were
incubated with ethidium homodimer 1 (1µg ml−1 in PBS)
for 5 min, washed and mounted in Vectashield mounting
medium (Vector Laboratories) and visualized using a Leica
TCS-NT confocal laser-scanning microscope (CLSM).
Measurement of glycine uptake
Epithelial uptake measurements were performed
essentially as described previously (Christie et al. 2001).
Cell monolayers (grown on 12 mm diameter filters)
were washed three times in 250 ml Krebs buffer (buffer
composition in mmol l−1: NaCl, 140; KCl, 5.4; CaCl2,
2.8; MgSO4, 1.2; NaH2PO4, 0.3; Hepes, 10; glucose,
5; pH to 7.4 at 37◦C with Tris base), Na+-free Krebs
buffer (composition as above except that choline chloride
replaced NaCl and NaH2PO4 was omitted), or Cl
−-free
Krebs buffer (composition as for Krebs buffer except
that NaCl, KCl and CaCl2 were replaced with the
corresponding gluconate salt) as stated. The experimental
composition of buffer in both the apical and basal
compartments was identical. Radiolabelled glycine was
used at tracer concentration (0.5µCi ml−1), with glycine
added to give a final concentration of 5µmol l−1 (unless
stated). 3H- and 14C-labelled glycine were used to measure
apical and basolateral uptake, respectively, in the same cell
population. Cells were incubated routinely for 10 min,
unless otherwise stated, after which time the cells were
washed three times in 250 ml volumes of ice-cold Krebs
buffer, Na+-free, or Cl−-free buffer (pH 7.4) to remove any
loosely associated radiolabel. The filter was removed from
the insert and cell monolayer-associated radioisotope was
measured using dual-label scintillation counting, with
appropriate corrections for quench, channel spillover, and
efficiency, using a Beckman LS 5000CE liquid scintillation
counter (Beckman Instruments, High Wycombe, UK).
For determination of glycine uptake kinetics,
accumulation was measured as described (Christie et al.
2001) over a glycine concentration range of 0–1 mmol l−1
and in the presence of mannitol to ensure equal osmolarity.
Unlabelled glycine at 1 mmol l−1 was added to measure
non-mediated (non-saturable) uptake. Carrier-mediated
uptake was calculated by subtracting non-mediated from
total uptake. Values given in the text and figures are
for mediated uptake only. Plots of uptake rate versus
glycine concentration were fitted by non-linear regression
to Michaelis–Menten kinetics. Each experiment, in which
each measurement was made on three separate filters, was
repeated at least twice.
Statistical analysis
Experiments were performed routinely in triplicate and
each experiment was repeated at least twice. Results are
expressed as means± S.E.M. Statistical comparisons were
made using one-way ANOVA and Dunnett’s post hoc test
(Prism, Graphpad Software Inc., San Diego, CA) or by
Student’s paired t test. Differences between means were
considered significant at P < 0.05. Kinetic constants for
Michaelis–Menten kinetics were calculated by nonlinear
regression analysis using commercially available software
(Prism).
Results
Effects of glycine on t-BOOH-induced cell injury
Cell viability, assessed by measuring the ability of cells
to reduce MTT, was used as an indicator of cytotoxicity.
The protective effects of glycine against oxidative stress
were investigated by either incubating colonocyte-like
HCT-8 cells with glycine for 24 h prior to exposure to
150µmol l−1 t-BOOH for 24 h or by concurrent exposure
to glycine and t-BOOH for 24 h. At this concentration
t-BOOH generally produced a reduction in cell viability
of 60–70%. Pre-incubation with 1 mmol l−1 or 5 mmol l−1
glycine reduced significantly the damage caused by sub-
sequent exposure to t-BOOH; cell viability was increased
from 28± 2% of control following t-BOOH, to 63± 7% of
control with 1 mmol l−1 glycine before t-BOOH exposure
(Fig. 1A). In contrast, concurrent glycine addition was
unable to ameliorate the reduction in cell viability induced
by t-BOOH (Fig. 1B). Exposing cells to glycine alone,
without t-BOOH exposure, had no effect, beneficial or
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detrimental, on cell viability (cell viability in the pre-
sence of 1 mmol l−1 glycine: 98± 4% of control (n= 6),
5 mmol l−1 glycine: 101.2± 5.2% (n= 6)). To investigate
the specificity of the response the effects of pre-treatment
with the amino acid alanine, which is structurally similar
to glycine, were investigated. Cells were incubated in
medium containing 3 mmol l−1 L-alanine for 24 h, after
which the culture medium was removed and replaced
Figure 1. Effect of pre- or concurrent treatment with glycine on
cell viability in response to t-BOOH treatment
A, glycine pre-treatment: HCT-8 cells were incubated in serum-free
medium or serum-free medium containing either 1 mmol l−1 or
5 mmol l−1 glycine for 24 h after which they were transferred to
serum-free medium containing 150 µmol l−1 t-BOOH for 24 h.
B, concurrent glycine treatment: confluent monolayers of HCT-8 cells
were incubated in serum-free medium containing 150 µmol l−1
t-BOOH or serum-free medium containing 150 µmol l−1 t-BOOH and
either 1 mmol l−1 or 5 mmol l−1 glycine for 24 h. Cell viability was
measured using the MTT assay. Results are shown as a percentage of
viability in control cells (open bars), which were maintained in normal
medium throughout with changes at appropriate time points, and are
means ± S.E.M. of three independent experiments performed on 12
replicates. In each chart, means without a common letter are
statistically different (P < 0.05).
with medium containing 150µmol l−1 t-BOOH for 24 h:
the same protocol as used previously for glycine. In
cells exposed to t-BOOH alone, viability was reduced to
42± 8% of control and alanine pre-treatment did not alter
this (viability in alanine pre-treated cells: 41± 2%).
The requirement for glycine pre-incubation prior
to oxidative challenge was indicative of a role for
glycine uptake in the protective mechanism. Therefore,
the involvement of GLYT1 was investigated. Trans-
porter activity was inhibited by incubating HCT-8 cells
with 30 nmol l−1 ALX-5407, a GLYT1 specific inhibitor
(Atkinson et al. 2001), prior to glycine or t-BOOH
treatment (see below). Incubation with ALX-5407 for
15 min prior to glycine pre-treatment completely blocked
the beneficial effects of glycine (Fig. 2A). When given
alone, i.e. in the absence of glycine supplementation,
GLYT1 inhibition exacerbated the effects of t-BOOH but
had no effect in unchallenged cells (Fig. 2B).
Expression and localisation of GLYT1 in human large
intestine and HCT-8 cells
The ability of ALX-5407 to antagonise the protective
effects of glycine is indicative of a role for GLYT1 in HCT-8
cells. Previously we have shown GLYT1 expression in
human small intestine and the Caco-2 cell model, but this
had not been demonstrated in large intestine or the HCT-8
model. PCR amplification of cDNA derived from HCT-8
cell mRNA with oligonucleotide primers specific to human
GLYT1 mRNA generated a single product of 409 bp, which
on sequencing was found to be identical to human GLYT1,
transcript variant 1 (Genbank accession no.: NM 006934)
between bases 1437 and 1845, confirming GLYT1 gene
expression in this cell line. Confocal immunofluorescence
microscopy localized GLYT1 protein to HCT-8 cell apical,
lateral and basal plasma membranes. Control reactions, in
which the GLYT1-specific antibody was omitted, showed
negligible staining (Fig. 3).
PCR analysis of a human digestive system cDNA
panel showed expression of GLYT1 throughout the large
intestine. GLYT1 mRNA concentration did not vary
greatly but was slightly higher in caecum, where it was
similar to that in human ileum (Fig. 4). In human colon,
GLYT1 protein was localised to the membrane of cells
lining the crypts with strong staining at both apical and
basal surfaces. Sections from three separate individuals
and from ascending, descending and transverse colon
showed identical patterns of immunofluorescence (Fig. 4,
results shown only for descending colon). In the absence of
anti-GLYT1 antibody, staining of human colonic tissue by
the AlexaFluor 488-conjugated secondary antibody was
negligible, showing that staining of the test sample was
specific for GLYT1.
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GLYT1 functional activity in HCT-8 cells
Glycine uptake in polarised layers of HCT-8 cells
was fivefold greater across the basolateral than the
apical membrane (basal uptake: 59.4± 3.2 pmol cm−2
(10 min)−1; apical: 11.8± 1.6; means± S.E.M., n= 6),
comparable to the asymmetry of glycine uptake reported
in Caco-2 cells (Christie et al. 2001). Consequently,
further investigations concentrated on basolateral glycine
uptake. This comprised three components identified by
differing ion dependence: Na+ dependent, Cl− dependent
and uptake dependent upon both Na+ and Cl−. Na+-
and Cl−-dependent uptake, characteristic of GLYT1,
accounted for 78.6± 6.30% of total glycine uptake and
was approximately fivefold higher than that in the
presence of Na+ alone (15.3± 1.32% of total glycine
uptake).
Kinetic analysis, as described in detail by Christie et al.
(2001) and performed in the presence of 5 mmol l−1
L-alanine to block Na+ only dependent glycine uptake,
showed that Na+- and Cl−-dependent glycine uptake
followed Michaelis–Menten kinetics describing one-site
binding with an apparent Michaelis constant (K m) of
103± 4µmol l−1 (n= 6) and a maximum velocity (V max)
of 18.5± 0.4 pmol cm−2 min−1. In these conditions, Na+-
and Cl−-dependent glycine uptake was inhibited only
by glycine, sarcosine and glycine ethyl ester, consistent
with the known specificity of GLYT1; L-serine and GABA
had no inhibitory effect. Finally, the contribution of
GLYT1 was confirmed by use of specific inhibitors of
GLYT1 and GLYT2, ALX-5407 and ALX-1393 (Xu et al.
2005), respectively, on glycine uptake. Monolayers were
incubated with the appropriate inhibitor for 15 min
prior to measurement of glycine uptake. ALX-5407, in
concentrations ranging from 10 nmol l−1 to 1µmol l−1,
inhibited significantly Na+- and Cl−-dependent baso-
lateral glycine uptake. Inhibition was approximately 40%
at 10 nmol l−1 and was maximal at 30 nmol l−1 and above,
reducing glycine uptake to 20–30% of that in control cells
(Fig. 5). Non-linear regression analysis showed ALX-5407
to be a high affinity antagonist of Na+- and Cl−-dependent
glycine uptake with an EC50 value of 9.6± 0.23 nmol l
−1.
ALX-1393 did not inhibit Na+- and Cl−-dependent
glycine uptake over the same concentration range (Fig. 5),
consistent with the lack of expression of GLYT2 in HCT-8
cells (results not shown). Thus, expression of GLYT1
mRNA and protein, the Na+ and Cl− dependence of
glycine uptake, substrate specificity, kinetic characteristics
and sensitivity to a specific GLYT1 inhibitor indicate
functional system GLY and specifically GLYT1 activity
in HCT-8 cells. As GLYT1 accounts for around 70% of
Na+- and Cl−-dependent glycine uptake, which in turn
represents nearly 80% of total glycine uptake, this is the
dominant mechanism for glycine uptake in these cells
confirming that this cell line, like Caco-2, is a suitable tool
to investigate the relationship between GLYT1 mediated
glycine uptake and cytoprotective activity of glycine.
Effect of glycine and t-BOOH on glycine uptake
Basolateral glycine uptake was measured in cells
treated with glycine for 4 h, t-BOOH for 1 h or a
Figure 2. Effect of the GLYT1 inhibitor ALX-5407 on
glycine-induced cell protection
A, HCT-8 cells were incubated in serum-free medium containing
5 mmol l−1 glycine or 5 mmol l−1 glycine plus 30 nmol l−1 ALX-5407
for 24 h after which they were transferred to serum-free medium
containing 150 µmol l−1 t-BOOH for 24 h. Data are compared with
those obtained from cells maintained in serum-free medium for 48 h
(open bar) and from cells exposed to 150 µmol l−1 t-BOOH following
incubation in serum-free medium for 24 h. B, cells were incubated in
serum-free medium with or without 30 nmol l−1 ALX-5407 for 24 h
after which they were transferred to serum-free medium containing
150 µmol l−1 t-BOOH for 24 h. Control cells (open bar) were
maintained in serum-free medium throughout. Cell viability was
assessed using the MTT assay. Results are expressed as percent of
control value and are means ± S.E.M. from 3 independent experiments
performed in triplicate. Means without a common letter are
statistically different (P < 0.05).
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Figure 3. CLSM images of fixed and permeabilised
HCT-8 cells showing GLYT1 staining (green)
throughout the cell membrane
Shown are a horizontal section (A) taken below the
apical plasma membrane and a vertical section (B) of a
polarised monolayer of cells. In the control reaction
(C) the GLYT1 specific antibody was omitted. The
monlayers were also stained with ethidium homodimer
(red, shown in A and C). Bar = 10 µm (A and C).
combination of glycine followed by t-BOOH. Glycine
had a concentration-dependent effect, with 5 mmol l−1
glycine increasing uptake, measured over 15 min, by
approximately 40%. In contrast t-BOOH decreased
glycine uptake regardless of whether cells had been
pre-treated with glycine or not (Fig. 6).
Glycine reduces ROS concentration in
t-BOOH-treated intestinal cells
To demonstrate the generation of ROS in cultured cells in
response to t-BOOH treatment, confluent monolayers of
Caco-2 and HCT-8 cells grown on 22 mm coverslips were
Figure 4. Expression and localisation of GLYT1 in
human large intestine
A, agarose gel elctrophoresis of products from PCR
amplification of human intestinal cDNAs using
GLYT1-specific primers. A single PCR product of
∼400 bp is visible for each sample. Lanes are: I, ileum;
I-C, ileo-caecum; C, caecum; A, ascending colon; T,
transverse colon; D, descending colon; R, rectum; L,
liver; K, kidney; N, negative control (ultra-pure water
replaced cDNA in the reaction). B, CLSM images of
frozen sections of human descending colon stained for
GLYT1. a, optical section (low power view) showing
GLYT1 expression in both apical and basal membranes
of cells throughout the colonic crypt. c–d, optical
sections (high power views), again showing GLYT1
expression in both apical and basolateral membranes of
cells in the crypt base. In the absence of anti-GLYT1
antibody (b) staining by the AlexaFluor 488-conjugated
detecting antibody is negligible. a and b, which show
the same region of consecutive sections, were collected
and displayed using identical parameters. L, crypt
lumen. Bar = 50 µm (a and b); 10 µm (c and d).
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Figure 5. Inhibition of Na+- and Cl−-dependent basolateral
glycine uptake by a GLYT1-specific inhibitor in HCT-8 cells
Effect of GLYT1 inhibitor, ALX-5407, and GLYT2 inhibitor, ALX-1393,
on basolateral, alanine-insensitive, Na+- and Cl−-dependent glycine
uptake in HCT-8 cells. Glycine uptake was measured in Krebs buffer in
the presence of 5 µmol l−1 glycine, 5 mmol l−1 alanine and increasing
concentrations of either ALX-5407 (¤) or ALX-1393 (¥) over 10 min.
Results are expressed as means with error bars of ± S.E.M., n = 6.
pre-loaded with H2DCFDA, incubated with 100µmol l
−1
t-BOOH for 60 min and visualised by CLSM. ROS, evident
as green fluorescence throughout the cell (Fig. 7), were
identified in a subset, approximately 20–30% of the total
population, of cells exposed to t-BOOH, and did not differ
between the cell types. Control cells, also loaded with
H2DCFDA, were maintained in normal culture medium
and showed little fluorescence.
To quantify the effect of glycine pre-treatment on ROS
generation, the assay was adapted to a 96-well plate
format and total fluorescence measured. For comparison
Figure 6. Effect of glycine and t-BOOH on basolateral glycine
uptake
Caco-2 cells were exposed to 5 mmol l−1 glycine, 150 µmol l−1
t-BOOH or glycine followed by t-BOOH, and basolateral glycine uptake
measured over 15 min in Krebs buffer containing 5 mmol l−1 alanine.
Results are expressed as means ± S.E.M., n = 6. Means without a
common letter are statistically different (P < 0.05).
purposes, the fluorescence of H2DCFDA following
t-BOOH treatment was normalised to Hoechst 33342
(DNA) fluorescence and set at 100%. Pre-treating cells
with 1 or 5 mmol l−1 glycine reduced ROS concentration
in response to t-BOOH challenge, indicated by a
decrease in relative fluorescence, to ∼75% of maximum
Figure 7. Effect of glycine and GLYT-1 inhibition on ROS
concentration
A, Caco-2 cells were incubated in serum-free medium containing 1 or
5 mmol l−1 glycine with or without 30 nmol l−1 ALX-5407 prior to
incubation with t-BOOH and determination of ROS concentration.
Control cells (maximum ROS concentration, open bar) were exposed
only to t-BOOH. Results are expressed as a percentage of maximum
and are means ± S.E.M. of three independent experiments performed
in triplicate. Bars without a common letter are statistically different
(P < 0.05). B, CLSM images of Caco-2 (a and c) and HCT-8 cells (b and
d) preloaded with carboxy-H2DCFDA and exposed to 100 µmol l
−1
t-BOOH (A and B) or normal medium (C and D) for 1 h. In the
presence of ROS the fluorescein compound is oxidised to carboxy-DCF
and emits bright green fluorescence. Images are shown at ×100
(a and c) and ×20 (b and d) magnification. Bar = 10 µm.
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(P < 0.05) (Fig. 7). Pre-treatment with 1 or 5 mmol l−1
L-alanine had no effect (ROS concentrations: 97.3± 2.95
and 99.6± 3.40% of maximum, respectively). When
GLYT-1 was inhibited by incubation with 30 nmol l−1
ALX-5407 for 15 min prior to glycine pre-treatment,
ROS concentration remained high indicating that GLYT1
inhibition prevented glycine protection (Fig. 7).
Glycine preserves intracellular glutathione during
oxidative stress
Exposure of HCT-8 cells to 150µmol l−1 t-BOOH for
24 h resulted in a >80% decrease in cellular total
GSH content (Fig. 8A). This was largely prevented by
pre-treatment with 5 mmol l−1 glycine for 24 h before
challenge, maintaining GSH concentration at ∼70% of
that in control cells. Cells exposed to 5 mmol l−1 glycine for
24 h, without subsequent exposure to t-BOOH, showed
no significant increase in glutathione content (Fig. 8A). In
Caco-2 cells, less extreme conditions which had no effect
on cell viability, 100µmol l−1 t-BOOH for 60 min, were
associated with a smaller decrease in GSH concentration
(to 77.5± 1.8% of control, P < 0.05) (Fig. 8B). Glycine
pre-treatment (5 mmol l−1, 4 h) prevented this and
returned GSH concentration to control level (99.6± 3.2%
of control; P < 0.01 compared with t-BOOH-treated).
L-Alanine had no effect on GSH concentration, either in
control or challenged cells (Fig. 8B). Inhibiting GLYT1
with ALX-5407 prior to glycine loading, in line with
its prevention of glycine protection and ROS generation
(Figs 2 and 7), prevented glycine maintenance of GSH
concentration (Fig. 8C). Pre-treatment with ALX-5407
alone did not exacerbate the effect of t-BOOH (Fig. 8C)
and in unchallenged cells the inhibitor had no effect on
GSH concentration either when given alone or with glycine
supplementation.
Abundance of mRNAs encoding GLYT1 and
GSH-related enzymes is not regulated by t-BOOH
or glycine
Previous studies have indicated that stress results in
up-regulation of GLYT1 gene expression (Harding et al.
2003) and that stimulation of GSH synthesis involves
increased expression of GCLC and, to a lesser extent,
GCLM and GS (Lu, 2009). Therefore we examined the
effect of glycine and t-BOOH on abundance of these
mRNAs. In Caco-2 cells, treatment with 5 mmol l−1
glycine for 4 h, 100µmol l−1 t-BOOH for 1 h or combined
glycine pre-treatment and subsequent t-BOOH had no
significant effect on abundance of any of the GSH-related
mRNAs investigated. Similarly, GLYT1 mRNA abundance
was not altered significantly by t-BOOH although
treatment with glycine, with or without subsequent
Figure 8. Effect of glycine and GLYT-1 inhibition on intracellular
GSH concentration during oxidative stress
GSH concentration was measured in HCT-8 cell monolayers incubated
in serum-free medium or serum-free medium containing 5 mmol l−1
glycine for 24 h followed by a further 24 h in serum-free medium or
serum-free medium containing 150 µmol l−1 t-BOOH (A), Caco-2 cell
monolayers incubated with serum-free medium alone or containing
5 mmol l−1 glycine or L-alanine for 4 h prior to exposure to
100 µmol l−1 t-BOOH for 1 h (B), and Caco-2 cells incubated in
serum-free medium containing 30 nmol l−1 ALX-5407 with or without
5 mmol l−1 glycine for 4 h and subsequent exposure to 100 µmol l−1
t-BOOH for 1 h (C). Results are shown relative to cells incubated in
serum-free medium throughout (open bars) and are means ± S.E.M.
of three independent experiments performed in quadruplicate. Means
without a common letter are statistically different (P < 0.05).
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Table 2. Relative mRNA abundance of GLYT1 and GSH-related enzymes in t-BOOH- and
glycine-treated Caco-2 cells
Treatment
Control Glycine t-BOOH Glycine + t-BOOH
GLYT1 100 ± 6 75 ± 5.1 102.8 ± 13.4 77.5 ± 11.4
GCLC 100 ± 1.9 105 ± 4.1 108.4 ± 2.9 103 ± 6
GCLM 100 ± 3.4 102 ± 7.8 111.3 ± 8.9 120 ± 7.1
GS 100 ± 5.3 122 ± 10.8 126.3 ± 10.2 108 ± 9.5
Values (expressed as percentage of control) are given as means ± S.E.M. n = 9–12 per
group and are means of 3–4 experiments. In all cases P > 0.05 compared to control.
t-BOOH, resulted in a non-significant decrease to
approximately 75% of that in control cells (Table 2).
Comparable results were obtained in HCT-8 cells treated
with 4 mmol l−1 glycine or 50–200µmol l−1 t-BOOH for
periods of 2–24 h (data not shown).
Discussion
Multiple studies have established that glycine is able
to protect intact intestine from injury caused by
ischaemia–reperfusion (Mangino et al. 1996; Iijima et al.
1997; Lee et al. 2001, 2002; Schaefer et al. 2008) and
it has also been demonstrated that it can prevent or
reverse the damage caused during the induction of
experimental colitis by TNBS and dextran sulphate or
abdominal irradiation in rodents (Tsune et al. 2003).
However, the underlying molecular mechanisms remain
unknown. Therefore, to provide a more tractable system
for such studies, we have established human cell models of
oxidative intestinal injury, and used these to investigate
glycine mediated intestinal cell protection. Moreover,
utilisation of these intestinal cell models allowed iso-
lation of the effects to intrinsic properties and functions of
the epithelial cells, distinct from any confounding effects
on extra-epithelial tissues or functions, such as neurone,
blood flow or immune responses.
The oxidising agent t-BOOH induced ROS formation
in both Caco-2 and HCT-8 cells and resulted in a
decrease in cell viability. Glycine, given prior to t-BOOH
challenge, reduced ROS concentration and protected cells
against damage. However, it had no protective effect when
administered simultaneously with t-BOOH, consistent
with a requirement for glycine accumulation by the cells.
That this is indeed the case was confirmed by inclusion of
the GLYT1-specific inhibitor ALX-5407, which blocked
the protective effects of prior exposure to exogenous
glycine against t-BOOH challenge. These data, supported
by the demonstration of expression of GLYT1 mRNA and
protein in human colon, where nutrient absorption is
minimal and is thus unlikely to be involved in assimilation
of dietary glycine, suggest that GLYT1 is essential for
cytoprotection by glycine and important in preserving
intestinal cell health.
Intestinal cells are exposed to constant and high levels
of oxidising agents and so require an efficient mechanism
for preserving cellular redox potential. Glutathione, the
most abundant antioxidant of the intestinal mucosa, is
generated in intestinal cells. It is required for intestinal
function (Martensson et al. 1990) and at times of
prolonged or severe stress the supply of its component
amino acids, including glycine (Jackson, 1986), becomes
essential. Additionally, glycine supplementation has been
shown to increase hepatocyte, erythrocyte and plasma
glutathione activity and protect against alcohol-induced
liver injury in rats (Senthilkumar et al. 2004). Therefore,
we examined the effect of glycine exposure on glutathione
concentration in intestinal cells during oxidative stress.
Prolonged exposure to t-BOOH reduced dramatically
glutathione concentration and this effect was reversed
partially by pre-treatment with glycine; less severe
treatment had a lesser effect that was completely reversible,
suggesting that accumulated glycine is used to replenish
glutathione.
In tissues such as kidney and liver, glycine cyto-
protection appears to be independent of glutathione levels
(Dickson et al. 1992; Weinberg, 1992) and instead works by
activation of the glycine receptor (GlyR), a glycine-gated
chloride channel (Gundersen et al. 2005). However, as
this requires extracellular glycine (Dong et al. 2001),
it is unlikely to be the active mechanism in intestinal
epithelial cells where we have clearly shown a dependence
on GLYT1-mediated glycine uptake. Furthermore, we also
demonstrated a requirement for glycine administration
prior to challenge which is not essential for GlyR mediated
protection (Miller et al. 1994), and found that L-alanine
was ineffective as a cytoprotectant. L-Alanine is a weak
agonist of the glycine receptor (Rajendra et al. 1997) and
has been shown to have similar, although lesser, protective
effects to glycine in tissues where GlyR protection has been
described (Silva et al. 1991; Weinberg et al. 1992; Marsh
et al. 1993; Zhang et al. 2003).
Evidence of GlyR-independent mechanisms of glycine
cytoprotection has also been found in other tissues.
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High concentrations of glycine (10–30 mM compared with
1–5 mM used here) protected lung endothelial cells against
gabexate mesilate-induced injury and appeared to work by
blocking the opening of membrane channels and pores in a
glycine receptor-independent mechanism (Aki et al. 2008).
Cytoprotection of liver cells by glycine has been observed
in the absence of chloride and calcium ions (Frank et al.
2000) in an as yet unexplained process. These differences
suggest multiple but not exclusive modes of action. Indeed,
our observations in intestinal cells differ from those of
Katayama & Mine (2007) who demonstrated increased
glutathione content and glutathione reductase activity in
oxidatively-stressed Caco-2 cells pre-treated with alanine
but showed no cytoprotection, indicated by a reduction in
IL-8 secretion, by glycine. However, there were significant
methodological differences between that work and ours,
including differences in cell culture conditions, nature
of oxidative challenge and measured indicators of stress,
supporting earlier conclusions that the mechanism of
protection is dependent on both cell/tissue type and the
nature of the challenge (Sogabe et al. 1996; Deters et al.
1998).
That we have shown GLYT1 dependence and increased
glutathione concentration in two human intestinal cell
lines grown under different conditions suggests that this is
a general mechanism relevant to the whole of the intestine.
Moreover evidence from other work supports a more
widespread role for GLYT1 in cytoprotection. GLYT1
mRNA expression was up-regulated in mouse fibroblasts
subjected to endoplasmic reticulum stress, mediated by
the transcription factor ATF-4, which plays a central role
in several stress response pathways (Harding et al. 2003).
Enhanced expression of other amino acid transporters,
particularly of xCT, the light chain of the transporter X−c
important in providing cells with cysteine for glutathione
synthesis, was also noted suggesting that part of the cellular
response to stress is to increase the availability of specific
amino acids required for the synthesis of essential proteins
and peptides.
In view of this and having shown altered glycine trans-
port in response to glycine and t-BOOH we examined
the effect of the various treatments on GLYT1 mRNA
abundance in our cell models. However, it was not changed
by any of the treatments, suggesting that in this system
GLYT1 transcriptional regulation is not a significant
factor. Furthermore as the antibody used in the localisation
studies proved unsuitable for Western blot analysis it was
also not possible to demonstrate whether the observed
changes in GLYT1 activity following glycine or t-BOOH
treatment were due to alterations in concentration of
the GLYT1 protein within the cell membrane. However,
that GLYT1 activity was reduced by t-BOOH may in
part explain the reduced effectiveness of glycine when
co-administered with t-BOOH.
Many previous studies have established a link
between expression of the glutathione-related enzymes
glutamate-cysteine ligase (GCL) and GS with GSH
concentration and shown that expression of the genes
encoding these molecules is upregulated in response to
stress and leads to stimulation of GSH synthesis. GCL
catalyses the first step of GSH synthesis, joining cysteine
and glutamate in a γ-linkage to form γ-glutamylcysteine
(γ-GC). It is a heterodimer composed of a catalytic
(GCLC) and a modifier (GCLM) subunit. Cellular GSH
content is correlated closely with GCLC and, to a lesser
extent, GCLM mRNA and protein content (Morales et al.
1997; Krzywanski et al. 2004; Suh et al. 2004; Takamura
et al. 2006). GS catalyses the second and final step of
GSH synthesis: the addition of glycine to γ-GC. Although
cysteine availability and GCLC expression are generally
thought to be the rate limiting factors in GSH synthesis,
evidence of co-ordinate regulation of GS, GCLC and
GCLM and work showing that increasing expression of
both GS and GCLC increases GSH synthesis to a greater
extent than increasing that of GCLC alone suggests that
GS may be of greater significance than previously thought
(Lu, 2009). As there appears to be a close correlation
between expression of these enzymes and de novo synthesis
of GSH we examined mRNA abundances to determine
if upregulation of transcription was required for the
maintenance of GSH concentration by glycine during
oxidative challenge. However, none of the treatments,
glycine, t-BOOH or a combination of the two (glycine
followed by t-BOOH), had an effect on abundance of any
of the mRNAs, suggesting that in this case, and as found
with GLYT1, transcriptional regulation of these enzymes
is not essential for glycine protection in this model. GCL
activity is regulated by GSH in a negative feedback loop and
by phosphorylation/dephosphorylation (Suh et al. 2004;
Lu, 2009). Thus it remains possible that de novo synthesis of
GSH rather than preservation of existing supply is involved
in glycine protection of intestinal cells.
It has been suggested that the fate of amino acids
taken up by intestinal cells is determined by the site of
acquisition, i.e. those absorbed from the gut lumen are
used in different processes than those acquired from the
serosal fluid, and that this is independent of the availability
of amino acid at the opposing surface (Reeds et al. 2000).
It is thus likely that the ‘source’ of a nutrient and the
mechanism by which it is acquired are dictated by the
specific use for which it is required. On the basis of
the experimental evidence presented here, we suggest
that glycine acquired across the basolateral membrane of
intestinal cells by GLYT1 is used in epithelial cell defence
and in maintaining intracellular antioxidant potential.
Further knowledge of the precise mechanism by which
glycine protects intestine and the role of GLYT1, including
regulation of expression and activity, may reveal potential
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for treatment of oxidative intestinal injury, including
inflammatory bowel disease.
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